Wellgistics Health, Inc. 8-K

What Happened
Wellgistics Health, Inc. announced on May 27, 2026 that it closed a private investment in public equity (PIPE) financing: the company issued convertible promissory notes with an aggregate principal amount of $21,132,812.50 for an aggregate cash purchase price of $16,906,250 (reflecting a 20% original issue discount). The Notes mature in 12 months, bear 0% interest, and are convertible into equity under specified terms; the financing also includes PIPE Warrants exercisable at $7.50 per share and Placement Agent Warrants exercisable at $6.25. The company used part of the proceeds to repay approximately $1.77 million owed to Marco Capital.

Key Details

• Notes: $21,132,812.50 aggregate principal issued for $16,906,250 cash (20% OID); 12‑month maturity; 0% interest; convertibility into Common Stock prior to a Mandatory Conversion Date.
• Conversion / Preferred: After specified conditions, outstanding Notes will convert automatically into Series A Convertible Preferred Stock (stated value $1,000/share); Series A accrues dividends of 10% annually beginning six months after issuance.
• Warrants and potential proceeds: PIPE Warrants exercisable at $7.50 (expire May 27, 2031); Placement Agent Warrants at $6.25. Full cash exercise of PIPE Warrants would yield ~ $39.6M (and ~$3.2M more if Placement Agent Warrants exercised), though exercise is not assured.
• Governance / limits: Beneficial ownership cap of 9.99% and an “Exchange Cap” of 19.99% apply; the company must seek stockholder approval under Nasdaq rules for issuances above the cap. Registration rights require filing within 15 days and effectiveness within ~45 days, with liquidated damages of 1.5% of the holder’s subscription amount per month for certain delays.

Why It Matters
This transaction provides immediate cash (net $16.9M) and pays down existing secured debt ($1.77M), which may help near-term liquidity. However, the notes and warrants add potential dilution if converted or exercised, and the company needs shareholder approvals and a registration statement to fully free the securities for resale and to permit issuances above the exchange cap. Investors should note the zero interest/short maturity of the notes, the automatic conversion mechanics into preferred stock, and the sizable potential equity overhang from warrants and conversions.